Multifocal motor neuropathy
ICD-10 G61.82 is a billable code used to indicate a diagnosis of multifocal motor neuropathy.
Multifocal motor neuropathy (MMN) is a rare, acquired disorder characterized by progressive weakness and atrophy of the muscles, primarily affecting the upper limbs. It is caused by a demyelinating process that affects multiple motor nerves, leading to asymmetric weakness and muscle wasting. Patients often present with symptoms such as muscle cramps, fatigue, and difficulty with fine motor tasks. The condition is distinct from other neuropathies due to its focal nature and the presence of conduction block on electrodiagnostic studies. Diagnosis typically involves a combination of clinical evaluation, nerve conduction studies, and electromyography (EMG), which reveal specific patterns of motor nerve involvement. MMN is often associated with anti-GM1 antibodies, and treatment may include intravenous immunoglobulin (IVIg) therapy, which can lead to significant improvement in muscle strength and function. Early diagnosis and intervention are crucial to prevent further disability and improve quality of life.
Detailed clinical notes including symptom onset, progression, and results of electrodiagnostic studies.
Patients presenting with asymmetric weakness, muscle cramps, and atrophy.
Ensure documentation includes antibody testing and treatment plans.
Functional assessments and treatment plans focusing on rehabilitation goals.
Patients requiring therapy for muscle weakness and coordination issues.
Documenting progress and response to therapy is crucial for coding.
Used to confirm diagnosis of MMN through nerve conduction studies.
Document the specific muscles tested and findings.
Neurologists should ensure comprehensive reporting of EMG results.
Performed to assess conduction block in suspected MMN cases.
Include details of the nerves tested and results.
Documentation must clearly indicate the rationale for testing.
Key symptoms include asymmetric muscle weakness, muscle cramps, and atrophy, primarily affecting the upper limbs.
Diagnosis is made through clinical evaluation, nerve conduction studies showing conduction block, and the presence of anti-GM1 antibodies.
Treatment options include intravenous immunoglobulin (IVIg) therapy, which can improve muscle strength and function.
